Carolina Jiménez González

Ms. Carolina Jiménez González

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
CGCarolina Jiménez González
Carolina Jiménez González
MAMarta Alonso-Peña
Marta Alonso-Peña
PVPaula Argos Velez
Paula Argos Velez
JCJavier Crespo
Javier Crespo
PIPAULA IRUZUBIETA
PAULA IRUZUBIETA
Gut microbiota has a crucial role in the pathophysiology of metabolic-associated steatotic liver disease (MASLD), influencing various metabolic mechanisms and contributing to the development of the disease. Dietary interventions targeting gut microbiota have shown potential in modulating microbial composition and mitigating MASLD progression. In this context, the integration of multi-omics analysis and artificial intelligence (AI) in personalized nutrition offers new opportunities for tailoring dietary strategies based on individual microbiome profiles and metabolic responses. The use of chatbots and other AI-based health solutions offers a unique opportunity to democratize access to health interventions due to their low cost, accessibility, and scalability. Future research should focus on the clinical validation of AI-powered dietary strategies, integrating microbiome-based therapies and precision nutrition approaches. Establishing standardized protocols and ethical guidelines will be crucial for implementing AI in MASLD management, paving the way for a more personalized, data-driven approach to disease prevention and treatment.

31 May 2025 in JHEP Reports
Verified
Journal Article
Open access
ASAnna Soria
Anna Soria
ADAlba M. Díaz
Alba M. Díaz
PIPAULA IRUZUBIETA
PAULA IRUZUBIETA
RMRosa Martin Mateos
Rosa Martin Mateos
MSM. Teresa Salcedo-Allende
M. Teresa Salcedo-Allende
IGIsabel Graupera
Isabel Graupera
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease worldwide. Autoantibodies (Ab), such as antinuclear antibodies (ANA) and anti-smooth muscle antibodies (ASMA), are frequently detected in MASLD, but their role in disease progression remains controversial. This study aimed to evaluate the prevalence of positive Ab and the histological features of autoimmune hepatitis (AIH) in MASLD and their association with liver-related outcomes. We conducted a multicenter, retrospective, longitudinal study of patients with biopsy-proven MASLD from the HEPAmet Registry. Data on ANA (≥1/80), ASMA (≥1/40), and AIH histological features (portal inflammation, interface hepatitis, and plasma cell infiltration) were analyzed for their association with compensated advanced chronic liver disease (cACLD), liver decompensation, and death. Of the 460 patients (49% women, median age 58 years, median BMI 33 kg/m2, and 45% with advanced fibrosis), 17% and 25% tested positive for ANA and ASMA, respectively. Histological features of AIH included interface hepatitis (19%), moderate/severe portal inflammation (12%), and plasma cell clusters (10%). Possible AIH based on histological criteria was present in 8% of patients. The presence of positive Ab was independently associated with cACLD development (odds ratio 2.890, p <0.030), liver decompensation (hazard ratio 3.969, p = 0.001), and death (hazard ratio 2.546, p = 0.036). In contrast, the presence of isolated histologic autoimmune features was not correlated with serological markers and did not affect the prognosis of MASLD. ANA and ASMA are commonly found in patients with MASLD and are associated with poorer liver-related outcomes and reduced survival, whereas isolated histological autoimmune features provide no additional prognostic value. Metabolic dysfunction-associated steatotic liver disease (MASLD) can coexist with other liver diseases, including autoimmune hepatitis. The role of autoantibodies and histological autoimmune features in MASLD progression remains controversial. Understanding the relationship between autoimmune characteristics and disease progression in MASLD may help physicians identify high-risk populations, enhance risk stratification, and personalize disease treatment.

23 July 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
CGCarolina Jiménez González
Carolina Jiménez González
PIPaula Iruzubieta
Paula Iruzubieta
MAMarta Alonso-Peña
Marta Alonso-Peña
LCLorena Cayón
Lorena Cayón
JCJavier Crespo
Javier Crespo
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide, and cardiovascular disease remains the leading cause of death in this population. Statins are therefore a cornerstone of therapy in MASLD because of their antiatherosclerotic efficacy. Less attention has been paid to the possibility that part of the hepatic benefit observed in MASLD cohorts—including lower aminotransferase levels, slower fibrosis progression, reduced decompensation and lower hepatocellular carcinoma incidence—may reflect direct hepatic effects beyond LDL reduction. Although the evidence is predominantly observational, the direction and magnitude of the association have remained broadly consistent across independent cohorts. Recent studies have strengthened this signal, including a post hoc analysis of the PROSPER trial showing attenuation of excess mortality in individuals with elevated FIB-4, and a large Veterans Affairs cohort demonstrating a dose-dependent association between cumulative statin exposure and lower primary liver cancer risk in MASLD. This review integrates the preclinical, observational and indirect randomized evidence supporting the biological plausibility of liver-directed effects of statins. Mechanistically, the argument centres on inhibition of the mevalonate pathway as a molecular hub linking lipotoxicity, NLRP3-dependent inflammation, fibrogenesis and carcinogenesis through impaired prenylation of small GTPases. A fifth axis, intrahepatic hemodynamics mediated through KLF2/eNOS signaling, is supported by randomized evidence in compensated cirrhosis. In contrast, the LIVERHOPE-EFFICACY trial showed no benefit in decompensated cirrhosis, helping define the therapeutic window. Within the limitations of the available evidence, we propose a conceptual reframing: in MASLD, statins may act not only as cardiovascular drugs, but also as agents with potentially relevant hepatic effects mediated through a shared molecular substrate.

24 April 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CGCarolina Jiménez González
Carolina Jiménez González
PVPaula Argos Velez
Paula Argos Velez
LCLorena Cayón
Lorena Cayón
AGANA BELEN GARCIA-GARRIDO
ANA BELEN GARCIA-GARRIDO
NGNoelia Fontanillas Garmilla
Noelia Fontanillas Garmilla
JCJavier Crespo
Javier Crespo
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide and a major contributor to the global cardiometabolic burden. Early identification of patients at risk of metabolic dysfunction-associated steatohepatitis (MASH) and advanced fibrosis is essential to prevent liver-related and cardiovascular complications. In Spain, the burden of MASLD is increasing, yet information on routine clinical management by gastroenterologists remains limited. Methods: A nationwide cross-sectional online survey was conducted among members of the Spanish Society of Digestive Diseases (SEPD). The questionnaire explored five domains: MASLD knowledge, use of non-invasive biomarkers and imaging, awareness and implementation of clinical guidelines, cardiometabolic and alcohol-related risk assessment, and coordination with primary care. Results: A total of 429 specialists responded, 33.1% reported more than 20 years of practice and most worked in public hospitals, including 29.2% in large tertiary centers. Awareness of the MASLD definition was high, and 91.2% identified fibrosis as the main prognostic determinant. Non-invasive fibrosis biomarkers were widely used, whereas steatosis biomarkers were less frequently applied. Elastography was available to 96.1%. Guideline knowledge was reported by 80.4%, although implementation was lower. Cardiovascular risk evaluation varied: 75.1% reported systematic screening. Alcohol consumption was usually assessed. Coordination with primary care was limited: 91.1% expressed concerns regarding physicians’ familiarity with MASLD classification, and only 31.1% reported shared protocols. Conclusions: Spanish gastroenterologists show high awareness of MASLD and broad access to non-invasive diagnostic tools. However, important gaps remain in cardiovascular and alcohol risk assessment, guideline implementation, and coordination with primary care.

Verified
Journal Article
Open access
PDF file
JCJavier Crespo
Javier Crespo
MAMarta Alonso-Peña
Marta Alonso-Peña
CGCarolina Jiménez González
Carolina Jiménez González
LCLorena Cayón-González
Lorena Cayón-González
PIPAULA IRUZUBIETA
PAULA IRUZUBIETA
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a systemic disorder in which cardiovascular, hepatic and oncological outcomes shape long-term prognosis. Statins are particularly relevant because their cardiovascular benefit is firmly established, yet they remain underused in MASLD, while their potential liver-related effects remain uncertain. Observational studies consistently associate statin exposure with slower fibrosis progression, fewer major adverse liver outcomes, lower hepatocellular carcinoma incidence and reduced liver-related mortality. However, direct randomized evidence in MASLD remains limited, and available studies differ substantially in disease stage, exposure, endpoint and follow-up. In this narrative review, we critically examine the cardiovascular, hepatic, oncological, randomized, observational, genetic and pharmacological evidence on statin therapy in MASLD. We aim to clarify the apparent discordance between evidence sources, assess whether statins may modify liver-related outcomes beyond their established cardiovascular benefit, and propose a framework for evaluating multidomain therapeutic effects. We propose outcome convergence as a framework for assessing whether a therapy can improve more than one clinically relevant disease domain while preserving independent causal evaluation of each outcome. Statins should therefore be regarded as a candidate, rather than an established, outcome-convergent therapy.

29 December 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
JCJavier Crespo
Javier Crespo
PVPaula Argos Velez
Paula Argos Velez
MAMarta Alonso-Peña
Marta Alonso-Peña
LCLorena Cayón
Lorena Cayón
CGCarolina Jiménez González
Carolina Jiménez González
PIPAULA IRUZUBIETA
PAULA IRUZUBIETA
Metabolic dysfunction–associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease worldwide, distinguished by pronounced clinical heterogeneity and a frequent dissociation between metabolic risk factors and the degree of hepatic injury. These observations, together with the limited contribution of genetic heritability, have prompted a re-evaluation of the traditional conceptual framework of the disease. In this context, the question has emerged as to whether MASLD could be, at least in part, transmissible condition. While there is no evidence to suggest that MASLD is contagious in humans, as no data support person-to-person transmission, gnotobiotic animal studies demonstrate that human gut microbiota can transfer susceptibility to steatosis, inflammation, and systemic metabolic disturbances through immunometabolic mechanisms, independent of host genetics. In parallel, human studies involving microbiota-targeted interventions support the concept that the gut ecosystem is a modifiable determinant of metabolic and hepatic phenotypes. Crucially, these findings do not imply natural transmission of disease, but rather underscore the functional plasticity of microbiota-host interactions. This narrative review integrates epidemiological, experimental, and clinical data to explore the hypothesis that MASLD may be functionally transmissible. MASLD is increasingly recognized as an eco-biological disease, where liver disease risk is not only shaped by host genetics and environment, but also by the ecological configuration and functional outputs of the gut microbiome. This perspective redefines disease susceptibility as, in part, context-dependent and microbiota-mediated, without implying infectiousness in the traditional sense.